secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001171843-23-006441
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst enrolls first patient in proof-of-concept trial for oral Factor D inhibitor BCX10013
--------------------------------------------------------------------------------

- First patient enrolled in open-label, multicenter dose-escalation trial of BCX10013 in up to 15 PNH patients.
- Primary endpoints: treatment-emergent AEs, graded lab abnormalities; secondary: LDH, hemoglobin, transfusion-free rate.
- If best-in-class profile confirmed in PNH, company plans to advance to pivotal program in renal complement diseases like IgAN.
- Trial conducted in countries without standard-of-care complement inhibitor therapy; NCT06100900.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/0001171843-23-006441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006441/f8k_102623.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer